This study provides a novel targeted therapeutic strategy for recurrent/refractory small cell lung cancer (SCLC), demonstrating the clinical feasibility of SEZ6 as a therapeutic target in neuroendocrine tumors, offering significant guidance for SCLC experimental design.
Literature Overview
This article, titled "SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial," published in Nature Medicine, systematically investigates the safety, pharmacokinetics, and preliminary efficacy of ABBV-706, an antibody–drug conjugate (ADC) targeting SEZ6, in patients with advanced solid tumors, particularly recurrent/refractory small cell lung cancer (SCLC). Through a dose-escalation and expansion design, the study identifies a recommended phase 2 dose and demonstrates significant antitumor activity.Background Knowledge
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy, accounting for approximately 11% of all lung cancers. Although first-line chemotherapy combined with immunotherapy can yield transient responses, most patients relapse within six months, and subsequent treatment options are extremely limited, with a median overall survival of less than one year. Currently, progress in targeted therapy for SCLC has been slow, primarily due to the lack of highly expressed, highly specific, and druggable surface targets. Objective response rates (ORR) for conventional chemotherapies such as topotecan or lurbinectedin are typically below 35%, while emerging bispecific T-cell engagers like tarlatamab show an ORR of around 40%, yet a large proportion of patients still do not respond. Therefore, there is an urgent need to develop new therapies with distinct mechanisms of action and durable efficacy. This study focuses on SEZ6—a neural lineage marker that is highly and broadly expressed in SCLC but nearly silent in normal tissues—as an ideal target for antibody–drug conjugates (ADCs). The high expression of SEZ6 makes it a potential dual-purpose target for both therapy and diagnosis, offering a new pathway to overcome current treatment bottlenecks.
Research Methods and Experiments
This study employed an open-label, multi-cohort phase 1 design, enrolling 288 patients with advanced solid tumors, of whom 240 received monotherapy with ABBV-706, including 124 with recurrent/refractory SCLC. The main cohorts included dose escalation (Part 1), SCLC dose optimization (Part 2a), and expansion in high-grade neuroendocrine tumors (Part 4). Patients received intravenous infusions of ABBV-706 every three weeks at doses ranging from 1.3 to 3.5 mg/kg. The study used a standard phase 1 design to determine the maximum tolerated dose and compared efficacy and safety between randomized 1.8 vs 2.5 mg/kg cohorts to establish the recommended phase 2 dose (RP2D). All patients were evaluated for safety, pharmacokinetics (PK), and immunogenicity, with efficacy analyzed in RECIST-evaluable patients. Key biomarker analyses included IHC detection of SEZ6 expression and dynamic monitoring of ctDNA.Key Conclusions and Perspectives
Research Significance and Prospects
This study establishes SEZ6 as a viable therapeutic target in SCLC, providing high-level clinical evidence for the application of ADCs in neuroendocrine tumors. The high response rate of ABBV-706 significantly surpasses that of current standard therapies, offering new hope for this difficult-to-treat population, especially in platinum-resistant/refractory patients. Its manageable safety profile supports long-term treatment, potentially extending disease control.
From a drug development perspective, this study validates the clinical feasibility of SEZ6-ADC, paving the way for confirmatory phase 2 trials (e.g., NCT07155174). Future research may explore combination strategies with immune checkpoint inhibitors or chemotherapy to further enhance efficacy. Additionally, the use of ctDNA as a dynamic biomarker warrants validation in larger cohorts and could enable personalized treatment adjustments.
Conclusion
This study marks a significant advancement in targeted therapy for small cell lung cancer. By precisely targeting SEZ6, which is highly expressed in SCLC, ABBV-706 achieved an unprecedented 52% objective response rate in heavily pre-treated patients, achieving an optimal balance between efficacy and safety at the 1.8 mg/kg dose. This finding not only provides a powerful new treatment option for patients with recurrent/refractory SCLC but also redefines the landscape of targeted therapy for neuroendocrine tumors. From bench to bedside, this study demonstrates a successful path from target discovery (SEZ6) to clinical translation (ABBV-706), laying a solid foundation for future biomarker-driven research, combination therapy exploration, and personalized treatment strategies. As confirmatory trials progress, ABBV-706 has the potential to become a new standard of care for second-line or later treatment of SCLC, significantly improving patient survival and quality of life.
